← All trials
NCT04367844
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Jul 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Apr 29, 2020
- Last posted
- Apr 29, 2020
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.